hotspot -WSS

hotspot

author：leisure time 2025-09-02 17:51:16 - browse：58

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： NIH nominee Bertagnolli will get October confirmation hearing

WSS

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

What drug price negotiations mean for Medicare Part D

The 10 drugs up first for Medicare price negotiation

Patients, doctors press FTC to beef up hospital merger scrutiny

Weighted lottery helped low

David Liu startup to focus on CRISPR delivery

focus

hotspot

Wikipedia

Alkermes shareholders re

How to fix cancer clinical trials' diversity problem

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Hepatitis C has a cure — but many Americans still lack access to it

Why Novartis is changing the name of its research labs

Dobbs anniversary: the lost opportunity of abortion as health care

Stem cell treatment guidelines are released by FDA

After affirmative action ruling, medical educators look to 'holistic review'

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Why Novartis is changing the name of its research labs

Neurocrine congenital adrenal hyperplasia trial succeeds

'Make People Better': The CRISPR babies story you probably don't know

Trump surgeon general acknowledges mistakes during Covid

Transgender sports debate: Physicians say bans are health issue

hotspot

hotspot

leisure time

Wikipedia